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Assessment of a carbon dioxide laser for the measurement of thermal nociceptive 1 
thresholds following intra-muscular administration of analgesic drugs to pain-2 
free female cats. 3 
 4 
 5 
Abstract 6 
 7 
Objective: To assess the potential for using a thermal carbon dioxide (CO2) laser to 8 
assess anti-nociception in pain-free cats.  9 
 10 
Animals: Sixty healthy adult female cats with a mean weight (± SD) of 3.3 kg (± 0.6 11 
kg). 12 
 13 
Methods: This is a prospective, blinded and randomised study. Cats were 14 
systematically allocated to one of six treatments 1) saline 0.2 ml/cat; 2) morphine 0.5 15 
mg/kg; 3) buprenorphine 20 µg/kg; 4) medetomidine 2 µg/kg; 5) tramadol 2mg/kg; 6) 16 
ketoprofen 2 mg/kg. Latency to respond to thermal stimulation was assessed prior to 17 
intramuscular injection and at 6 time periods following injection (15-30; 30-45; 45-18 
60; 60-75; 90-105; 120-135 min). Thermal thresholds were assessed using time to 19 
respond behaviourally to stimulation with a 500 mW CO2 laser with maximum 20 
latency to respond set at 60 seconds. Differences in response latency for each 21 
treatment across the duration of the experiment were assessed using a Friedman’s test. 22 
Differences between treatments at any given time were assessed using an independent 23 
Kruskal-Wallis test. Where significant effects were identified, pair-wise comparisons 24 
were conducted at 30-45, 60-75 and 120-135 min to further explain the direction of 25 
the effect. 26 
  27 
 Results: Cats treated with morphine (χ2 = 12.90; df = 6; P = 0.045) and tramadol (χ2 28 
= 20.28; df = 6; P = 0.002) showed significant increases in latency to respond over the 29 
duration of the test period. However, subsequent pairwise comparisons indicated that 30 
latencies at specific time points were only significantly different (P < 0.05) for 31 
tramadol at 60-75 and 90-105 min after administration. No significant pairwise 32 
comparisons were found within the morphine treatment group.  Injection of saline, 33 
ketoprofen, medetomidine or buprenorphine showed no significant effect on latency 34 
to respond.  35 
 36 
Conclusions: This project further validates the CO2 laser technique for use in cats. It 37 
can be used for assessment of thermal nociceptive  thresholds in pain-free cats after 38 
analgesic administration and shows some promise in differentiating amongst 39 
analgesic treatments. It may provide a simpler alternative to existing systems although 40 
further exploration is required both in terms of its sensitivity and comparative utility 41 
(i.e. relative to other thermal threshold systems). Future experiments should seek to 42 
quantify the effects of skin temperature and sedation on latency to respond. Given that 43 
this technique was found to cause minor skin blistering in individuals that reached the 44 
60 s exposure limit, a cut off time of <45 s is recommended. 45 
 46 
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 48 
Introduction 49 
 50 
Domestic cats (Felis catus) have previously been identified as underexplored in terms 51 
of their responses to pain and analgesia but significant advances have been made 52 
(Robertson 2008). Evidence suggests that cats, as a species, display substantial 53 
variation in their response to different classes of analgesic compounds (Taylor et al. 54 
2001; Robertson & Taylor 2004). Likewise there appears to be a large degree of inter-55 
individual variation around specific analgesic effects and pharmacodynamics, 56 
particularly with opioids (Lascelles & Robertson 2004; Johnson et al. 2007; Giordano 57 
et al. 2010; Steagall et al. 2013). These differences, as well as variations in injuries 58 
and clinical procedures, make extrapolation of effects from other species, or even 59 
between individuals of the same species, difficult (Steagall & Monteiro-Steagall 60 
2013). Research into techniques that allow pain and analgesic effects in cats to be 61 
objectively assessed is therefore prudent. 62 
 63 
Thermal assessment techniques have been validated for use in cats. These include 64 
both contact devices (Dixon et al. 2002) and remote CO2 laser stimulation (Farnworth 65 
et al. 2013b). Although the contact devices have been extensively explored and 66 
applied (Robertson et al. 2003; Steagall et al. 2007; Taylor et al. 2007a), the latter 67 
technique has only been validated in terms of its intra-individual repeatability 68 
(Farnworth et al. 2013b) and inter-individual variability (Farnworth et al. 2013a). It 69 
has not yet been used to explore the effects of pharmacological manipulation of 70 
nociceptive thresholds. Research in other species suggests that the CO2 laser may be a 71 
valid tool for the assessment of nociception (Herskin et al. 2003; Guesgen et al. 2011; 72 
Di Giminiani et al. 2013) although its ability to measure variations in pain 73 
experienced post-castration are inconclusive (Ting et al. 2010). The potential to use 74 
the laser technique with only moderate alteration of management routines and without 75 
substantial need for habituation required by other techniques (Slingsby & Taylor 76 
2008; Slingsby et al. 2010), suggest it could be a useful tool if validated further. 77 
 78 
Analgesics that act primarily upon the dorsal horn of the spinal cord are considered to 79 
have central effect (Robertson & Taylor 2004). This central action has been shown to 80 
result in thermal hypoalgesia (Dixon et al. 2002).  Effectiveness was established 81 
relative to two confirmed centrally-acting analgesics, morphine (pure mu-agonist) and 82 
buprenorphine (a partial opioid mu-agonist and antagonist of kappa-receptors) which 83 
have previously been evaluated in cats using thermal thresholds (Robertson et al. 84 
2003; Steagall et al. 2006; Pypendop et al. 2008). Medetomidine, an alpha-two 85 
agonist with both sedative and analgesic effects (Cullen 1996; Steagall et al. 2009b) 86 
was also used. Previous thermal threshold studies have been successfully conducted 87 
with respect to its active isomer dexmedetomidine (Slingsby & Taylor 2008). In 88 
addition two other compounds with analgesic activity were evaluated, all of which 89 
have received some attention in the literature. Tramadol has been validated using a 90 
thermal stimulus (Pypendop et al. 2009) and is a centrally acting synthetic analogue of 91 
codeine (Cagnardi et al. 2011). Ketoprofen is a non-steroidal anti-inflammatory drug 92 
(NSAID) and an effective analgesic following ovariohysterectomy in cats (Slingsby & 93 
Waterman-Pearson 1998). NSAID do not have a central action, but rather act to 94 
inhibit prostaglandin synthesis and therefore inflammatory response (Robertson & 95 
Taylor 2004).  96 
 97 
This research sought to explore the effectiveness of a CO2 thermal laser for the 98 
assessment of nociceptive thresholds in pain-free cats under analgesia. If this 99 
technique is to be considered useful for assessment of analgesia, latency to display a 100 
behavioural response should allow distinctions to be made between cats treated with 101 
one of the five compounds known to have analgesic effects (morphine, 102 
buprenorphine, tramadol, ketoprofen, or medetomidine) as compared to a saline 103 
control group. We hypothesised that latencies to respond to thermal stimulation will 104 
differ within the morphine, buprenorphine, tramadol and medetomidine treatment 105 
groups over the duration of the test period but not for saline or ketoprofen which has 106 
peripheral anti-inflammatory effects which are likely absent in these test subjects.  107 
 108 
Materials and methods 109 
 110 
Cats and housing conditions 111 
 112 
All procedures were approved by the Massey University Animal Ethics Committee 113 
(MUAEC protocol 12/109). A total of 60 adult female domestic cats were used, 32 114 
entire and 28 spayed, with a mean weight (± SD) of 3.3 (± 0.6) kg and a mean age (± 115 
SD) of 6.1 (± 3.1) years. The cats were permanently housed in a nutritional research 116 
facility in stable colonies of 10 individuals. Each colony was housed in an outdoor 117 
pen (2.4m height x 1.4m width x 4.4m depth) with approximately half the volume of 118 
each pen under cover. Cats included had no long-term medical conditions identified in 119 
their records (which were updated weekly) nor abnormal gait or substantial 120 
fluctuations in weight. They were therefore considered to be healthy and pain-free 121 
although no blood analyses were performed to categorically confirm this. As 122 
treatment allocation was determined only shortly before commencement of the 123 
experiment, food was not withheld in the colony housing and all subjects were fed a 124 
standard wet cat food diet ad libitum throughout the trial. Adverse side effects of 125 
treatment, such as excessive salivation or vomiting, were recorded during the 126 
experimental phase.  127 
 128 
During testing, cats were individually held in eight metabolism cages (0.8 m height x 129 
0.8 m width x 1.1 m depth) in a non-climate controlled room adjacent to, but separate 130 
from, the colony housing area (see Hendriks et al., 1999). These cages were regularly 131 
used for nutritional trials during which the cats were isolated and allowed to feed. The 132 
cats were, therefore, familiar with the cages and single housing, avoiding the need to 133 
acclimate the subjects. Prior to the cat being introduced to the cage, the depth of each 134 
cage was reduced to 0.55 m using a cardboard wall to ensure the cat did not have 135 
access to a shelf at the rear of the cage and to prevent reflection of the laser from the 136 
plastic rear wall. The metal cage door was replaced with a plasticated square mesh 137 
with openings measuring 25 x 25 mm to prevent reflection of the laser and subsequent 138 
injury to the subjects or operators. For the cats’ comfort, and to encourage sternal 139 
recumbency, each cage was furnished with a small wooden box, blanket, and litter 140 
tray. Food and water were not provided in the individual cages during the test phase.  141 
 142 
Laser device 143 
 144 
Thermal nociceptive thresholds were measured using a remote laser device (Model 145 
48-1, Synrad, Mulkiteo, Washington, USA) which was mounted on a tripod to allow 146 
movement through vertical and horizontal planes. The CO2 laser produced a 3.5mm 147 
diameter beam which was aimed using a non-thermal visible helium laser (JG-4A 148 
Class IIIA, wavelength 532nm) attached to the external casing. The wavelength of the 149 
thermal laser was 10.60 µm (far infra-red) and the maximum power output was 10 W. 150 
For the purposes of this experiment a 5% output was used (500 mW). Given that the 151 
non-visible component of the laser was potentially hazardous safety goggles were 152 
employed by the experimenters at all times. 153 
 154 
The visible (non-thermal) helium laser used to guide the thermal CO2 laser has 155 
previously been demonstrated to have no discernable effect on the behavioural 156 
response latency of cats (Farnworth et al. 2013b) therefore it was not used as a control 157 
in this experiment. In a previous study using cats, all responses to 500mW thermal 158 
stimulation occurred in less than 60 s (Farnworth et al. 2013a), therefore 60 s was set 159 
as the maximum duration for exposure to the thermal stimulus.  160 
 161 
Thermal threshold testing procedure 162 
 163 
The study was conducted over five days in February 2013. Approximately 24 h prior 164 
to the commencement of testing each cat’s fur was clipped to skin level on both sides 165 
of the thorax as per the technique outlined in Farnworth et al. (2013a). The cats were 166 
not removed from their colony cages during this procedure. For each cat, age, current 167 
body weight and whether they had been spayed were taken from their records. Each 168 
cat was systematically allocated to one of six treatment groups by ordering their 169 
names alphabetically and sequentially allocating them to group 1 through 6, the 170 
primary researcher (MF) was blinded to this systematic approach. Likewise 171 
individuals were systematically allocated to a test day meaning treatments were 172 
distributed across all test days as opposed to any single treatment being conducted on 173 
any single day. All tests were conducted between 0900 h and 1700 h. The total test 174 
period for each group was approximately 150-165 min. 175 
 176 
For testing, each group of eight cats was transferred to the experimental cages and 177 
was only returned after all nociceptive tests had been conducted on all group 178 
members. On introduction to the test cage cats were allowed 15 min to settle. The 179 
experimenters and equipment remained in the room during this time to habituate the 180 
cats to their presence. On commencement of the test sequence the majority of the cats 181 
were quiet and in sternal recumbency. 182 
 183 
Each cat was exposed seven times to a CO2 thermal laser device during the test 184 
period. Cats were not returned to the colony cages between tests. The laser was 185 
directed onto the exposed area of skin from a distance of 2 m until the cat responded 186 
either by shifting significantly (i.e. rising to its feet or significant easing of the body) 187 
or exhibiting the panniculus reflex, or until the pre-determined cut-off time of 60 s 188 
was reached (Farnworth et al. 2013a). Following either of these behavioural responses 189 
the laser was turned off. Deactivation of the laser device was manual. As this 190 
introduced a margin of error based on the researcher’s reaction time, the subject’s 191 
latency to respond (time) was noted to the nearest 0.1 s. The researchers attempted to 192 
avoid stimulation of the same area of skin during subsequent tests on any given 193 
subject. To minimise variations in the distance of the laser from the cat a line of tape 194 
was placed on the floor 2 m from the front of the cage, the front leg of the tripod, on 195 
which the laser was mounted, was placed on this line each time the laser device was 196 
moved. In the event that a cat was disturbed during testing (e.g. by the actions of an 197 
adjacent cat or staff activity), or moved incidentally (e.g. began to groom or urinate) 198 
the test was terminated and restarted as soon as possible (i.e. once the cat had 199 
resettled). Following an appropriate response the thermal laser was not re-applied 200 
until a minimum of 15 min had elapsed. The exact time between each test varied 201 
depending upon the activity pattern of the individual (i.e. time to sternal recumbence). 202 
 203 
The first thermal test was conducted for each cat prior to drug administration to 204 
establish a baseline response. The primary researcher (MF) then exited the room to 205 
ensure they were blind to treatment and the appropriate drug was then injected by a 206 
qualified veterinarian (LB). Latency to respond to thermal stimulation was measured 207 
during the following time intervals: 15-30; 30-45; 45-60; 60-75; 90-105; 120-135 208 
min. Intervals, rather than exact time points, were used as the cats were unrestrained 209 
and laser line-of-sight could not be guaranteed at any precise time. Where a reading 210 
could not be made within a 15 min interval the datum point was recorded as absent.  211 
 212 
Drug treatments 213 
 214 
Cats were randomly allocated to one of 6 treatments by the administering 215 
veterinarian, resulting in 10 cats per treatment group. The six treatments groups were 216 
1) saline (0.2 ml/cat; 0.9% NaCl; Baxter Healthcare Pty Ltd, Auckland, New 217 
Zealand); 2) morphine (0.5 mg/kg; morphine sulphate 10 mg/ml; Hospira, Mulgrave, 218 
Victoria, Australia); 3) buprenorphine (20µg/kg; Temgesic 0.3 mg/ml; Reckitt 219 
Benckiser, Auckland, New Zealand); 4) medetomidine (2 µg/kg; Domitor 1mg/ml;  220 
Pfizer, Auckland, New Zealand); 5) tramadol (2mg/kg; Tramal 50mg/ml; CSL 221 
Biotherapies, Auckland, New Zealand); 6) ketoprofen (3 mg/kg; Ketofen 10%; 222 
Merial, Auckland, New Zealand). For treatment group 4, a 1:10 dilution ratio 223 
(medetomidine:saline) was used to ensure injectable volume equivalence among 224 
treatments. All cats received an intramuscular injection into the epaxial muscles 225 
between the iliac crest and the last rib. Injection was made using a 22-gauge ¾ inch 226 
needle from a 1 ml syringe. 227 
 228 
Statistical analyses 229 
 230 
We used SPSS 22 (IBM inc., Chicago, Illinois, USA) to conduct our analysis. Our 231 
data was mostly nonparametric and our measures of central tendency and variation are 232 
expressed as median (range). We tested for differences in weight and age among 233 
treatment groups using a one-way ANOVA procedure. Prior to testing we first 234 
confirmed that data was normally distributed using the Kolmogov-Smirnov test and 235 
after testing for homogeneity of variance using the Levene’s test. 236 
 237 
Distribution of latencies to respond to thermal stimulation were not normal and so a 238 
non-parametric Friedman’s test was used to explore differences in response times 239 
across the duration of the monitoring period (135 min) for each of the treatments 240 
separately. For median calculations values exceeding 60 s were recorded as >60 s. 241 
 242 
The effect of treatment on latency to respond at a particular time period (e.g. 15-30 243 
min) was analysed by comparing response latencies between treatment groups at each 244 
of the seven time periods. This was done using an independent Kruskal-Wallis test.  245 
When a significant treatment effect was detected, pair-wise comparisons based on a 246 
Mann Whitney test were conducted to identify where specifically inter-treatment 247 
differences occurred. Given the large number of potential comparisons we restricted 248 
these to the period 60 – 75 min after injection of the drug or control and between the 249 
saline control and each of the drug treatments only (5 pair wise comparisons).We 250 
adjusted the p values using the Bonferroni correction (Critical value for significance 251 
(0.05)/number of comparisons) to reduce the likelihood of Type 1 errors. 252 
 253 
Results 254 
 255 
Weight and age 256 
 257 
We confirmed the variances in weight (Levene’s test, F(5,53) = 2.292,  P = 0.06) and 258 
age (Levene’s test, F(5,53) = 0.485,  P = 0.786) were homogenous and the distribution 259 
of data was normal for weight (Kolmogorov-Smirnvo test, P > 0.2 for each treatment 260 
group) and age (Kolmogorov-Smirnvo test, P > 0.074 for each treatment group)  261 
among treatment groups.  We could detect no differences in the body weights (F(5,53) = 262 
1.176, P = 0.33) or ages (F(5,53) = 0.278, P = 0.923)  of cats among the treatment 263 
groups This suggested we could disregard weight and age differences as potential 264 
explanations of different responses among treatments. 265 
 266 
Effect of treatments on latency to respond to thermal stimulation 267 
 268 
Readings were unable to be taken for 15/420 datum points. Of these, six datum points 269 
were absent in the saline group, four for ketoprofen, two for medetomidine, two for 270 
buprenorphine and one for morphine. Response times of cats to thermal stimulation 271 
were very variable across all six drug treatments (Fig 1). However median and total 272 
range of pre-treatment response times for cats that received either an analgesic drug or 273 
saline solution were always below 60 s (see Table 1). No significant effects of 274 
treatment with regards to the total test period, were found for the following 275 
treatments: saline (χ2 = 3.922; df = 6; P = 0.687), medetomidine (χ2 = 3.077; df = 6; P 276 
= 0.799) and ketoprofen (χ2 = 5.816; df = 6; P = 0.444). Although treatment with 277 
buprenorphine had no significant effect there was a suggestion that latency to respond 278 
did increase during the test phase (χ2 = 10.929; df = 6; P = 0.091). In contrast median 279 
response times of cats injected with morphine and buprenorphine were greater than 60 280 
s on at least one of the post-treatment time intervals. Treatment with morphine (χ2 = 281 
12.90; df = 6; P = 0.045) and tramadol had a significant effect on latency to respond 282 
(χ2 = 20.28; df = 6; P = 0.002) over the course of the monitoring period. The number 283 
of tests which reached the 60 s cut-off point are shown in table 2. 284 
_____________ 285 
Tables 1 and 2 here 286 
_____________ 287 
 288 
 289 
 290 
___________ 291 
Figure 1 here 292 
___________ 293 
For those analgesics for which we demonstrated a significant effect of latency to 294 
respond across the duration of the monitoring period we conducted a series of pair 295 
wise comparisons to determine whether the difference occurred at 30-45 min, double 296 
this time (60-75 min) and double this time again ( 120-135 min)  when compared to 297 
the response time immediately prior to injection of the analgesic drug. This 298 
represented three pairwise comparisons and we adjusted our threshold value for 299 
significance to P = 0.0167. 300 
 301 
For tramadol, significant differences were recorded between the pre-treatment 302 
[median(range) = 11.0 s (3.6-18.1)] and 60-75 min after treatment [21.9 s (12.2- >60 303 
s)]  (Z = -2.803, P = 0.005) and 120-135 min after treatment[29.7 s (9.5 – >60 s)]  (Z 304 
= -2.803, P = 0.005). Similarly we recorded significant differences for morphine 305 
treatment at the same time intervals namely pre-treatment [median(range) = 8.7 s (1.3-306 
27.8)]  and 60-75 min ([median(range) = > 60 s (17.9 - >60)]  Z = -2.701, P = 0.007) 307 
and pre-treatment and 120 -135 min [median(range) = 48.1 s (4.9->60)]   (Z = -2.599, 308 
P = 0.009 (Table 3,4).  We also determined the magnitude of the effect (effect size r) 309 
for these two way comparisons (Field 2009). Effect sizes for both tramadol and 310 
morphine were medium to large for both the pre-test vs. 60-75 min and pre-test vs. 311 
120-135 comparisons (Table 3). Similarly effect sizes for Buprenorphine fell within 312 
the range for tramadol and morphine. 313 
____________ 314 
Table 3 here 315 
____________ 316 
 317 
There was no significant effect of treatment on latency to respond to thermal 318 
stimulation during the pre-treatment interval (χ2 = 1.54; df = 5; P = 0.909), 15-30 min 319 
(χ2 = 4.68; df = 5; P = 0.456),  and 30-45 min (χ2 = 6.669; df = 5; P = 0.246) after 320 
injection However, a significant effect of treatment was detected at 45-60 min (χ2 = 321 
12.254, df = 5, P = 0.030), 60-75 min (χ2 = 21.02, df = 5, P = 0.001), 90-105 min (χ2 322 
= 18.38, df = 5, P = 0.003) and 120-135 min (χ2 = 11.72, df = 5, P = 0.039) after 323 
injection (Table 6). We followed up on the effect of treatment at the half way period 324 
of our trials (60-75 min) by using Mann-Whitney tests in a series of pair wise 325 
comparisons. The Bonferroni correction resulted in our effects being reported at a 326 
0.01 level of significance. There were no significant differences in latency to respond 327 
between cats injected with saline where compared to those injected with 328 
Buprenorphine (U = 20.0, P = 0.04), medetomidine (U = 40.0, P = 0.965), Tramadol 329 
(U = 16.0, P = 0.017) and ketoprofen (U = 37.0, P = 0.514). However latency to 330 
response was significant when saline treatment was compared to morphine treatment 331 
(U = 5.0, P = 0.001). Reflecting the fact that the Bonferroni correction provides a 332 
conservative indication of significance,  determination of an effect size of drug 333 
treatment on latency to respond indicated a medium effect of buprenorphine (-0.47) 334 
and tramadol  (-0.54)  in spite of the non-significant Mann-Whitney tests. The effect 335 
of ketoprofen was small (-0.149) and negligible for medetomidine (-0.01). Morphine 336 
showed a medium-large effect (-0.767) on latency to respond when compared with 337 
saline. 338 
 339 
Side effects of treatment and procedure 340 
 341 
Side effects associated with drug administration and application of the thermal 342 
stimulus were observed and subsequently reported to, and noted by, the ethics 343 
committee concerned with the approval of these protocols. Firstly, 24 h after the 344 
experiment, during routine checks, it was identified that 24/60 cats showed signs of 345 
mild blistering where the laser had been applied. Of the 24 cats with blistering 18 had 346 
reached the maximum exposure time of 60s on one or more occasion during testing. 347 
Blistering was dispersed across all treatment groups but was most prevalent in the 348 
morphine, buprenorphine and tramadol groups (5/10 individuals). Secondly there was 349 
evidence of nausea shortly after the administration of morphine. Eight of the ten cats 350 
in this group showed signs of excessive salivation or retching. 351 
 352 
Discussion 353 
 354 
A significant positive correlation between body weight and latency to exhibit a 355 
behavioural response has previously been demonstrated when using thermal 356 
stimulation (Farnworth et al. 2013a). In addition age-related changes in nociceptive 357 
sensitivity have been demonstrated in rodents (Chan et al. 1982, Jourdan et al. 2000). 358 
Our results indicated that these factors were not significantly different between 359 
treatment groups and therefore the likelihood that these factors substantially impacted 360 
upon the results is minimal. 361 
 362 
 363 
This study provides some evidence that a CO2 laser may be used to explore analgesic 364 
efficacy and can be used to distinguish between treatments that are known to have an 365 
analgesic effect and those that are not. In particular increased latency to respond to 366 
thermal stimulation was noted for morphine and tramadol. It is reassuring to note that 367 
no statistical difference was identified between baseline measurements for any 368 
treatment, although more than a single baseline measurement for each cat may have 369 
allowed clearer comparisons within treatments.  370 
 371 
A significant positive correlation between body weight and latency to exhibit a 372 
behavioural response has previously been demonstrated when using thermal 373 
stimulation (Farnworth et al. 2013a). In addition age-related changes in nociceptive 374 
sensitivity have been demonstrated in rodents (Chan et al. 1982, Jourdan et al. 2000). 375 
Our results indicated that these factors were not significantly different between 376 
treatment groups and therefore the likelihood that these factors substantially impacted 377 
upon the results is minimal. 378 
 379 
As expected no significant effects were found for groups administered saline or 380 
ketoprofen. Although, as for other NSAIDs (e.g. carprofen: Taylor et al. 2007c), 381 
ketoprofen is an effective analgesic when administered post-operatively (Tobias et al. 382 
2006), it is generally not expected to have analgesic effect which can be elucidated 383 
through thermal stimulation in pain-free cats. This is because NSAID analgesics act 384 
by reducing inflammation and, therefore, nociceptor activation (Le Bars et al. 2001). 385 
This non-response to both saline and an NSAID has been used to validate other 386 
emerging nociception assessment techniques in pain-free cats (Steagall et al. 2007). 387 
 388 
The morphine dose used here was high relative to that used in other studies. However, 389 
as for other studies (0.2 mg/kg, subcutaneously: Steagall et al. 2006) a significant 390 
change in threshold response was observed at around 60 min. A previous study with 391 
intramuscular injection at lower doses (0.2 mg/kg: Robertson et al. 2003) showed no 392 
significant changes in thermal threshold until 4-6 h following injection. Epidural 393 
administration (0.1 mg/kg: Castro et al. 2009) also resulted in significant reduction in 394 
nociceptive response to a tail clamp between 1-12h. 395 
 396 
Tramadol has been shown to significantly increase thermal thresholds 45 min after 397 
subcutaneous administration at 1 mg/kg, but with otherwise limited effect (Steagall et 398 
al. 2008). Significant increases in thermal threshold, measured using an attached 399 
device with a heating element, have been observed to persist between 45-90 min 400 
following intramuscular injection of tramadol at a dosage of 2 mg/kg (Jiwlawat & 401 
Durongphongtorn 2011) which compares well with the results obtained in this 402 
experiment (Fig. 2). Further studies comparing the different thermal techniques would 403 
be beneficial. 404 
 405 
Buprenorphine did not demonstrate a clear significant effect on thermal nociceptive 406 
thresholds. Studies using intravenous (Steagall et al. 2009a) and subcutaneous 407 
(Steagall et al. 2006) administration of buprenorphine at the same dose as this study  408 
demonstrate a clear effect on thermal threshold when using the thermal device 409 
developed by Dixon et al. (2002) within 15 min and 45 min of administration 410 
respectively. The former was effective for up to 4 h. Loss of significance across the 411 
sample may result from higher inter-individual variation in latency to respond to a 412 
low output thermal laser (Fig. 1.). Our data suggest that the response of individual 413 
cats may also be highly variable at the same dose with some individuals rapidly 414 
reaching out cut-off time whilst others demonstrated relatively little change across the 415 
testing period. It is also worthy of note that cats reached the 60 s cut-off point during 416 
the final test within the saline treatment group. Although a definitive reason cannot be 417 
provided for this it is likely that the extended testing period resulted in increased 418 
stress for some cats. Habituation to this length of study period may be required for 419 
these cats. 420 
 421 
In general our data showed substantial over-dispersion (see Table 1; Fig. 1). There 422 
were clear differences in latencies to respond amongst cats within the same treatment 423 
at a given time point. Opioids in general are known to elicit substantial inter-424 
individual variability in cats (Taylor et al. 2007b), this variability has recently been 425 
discussed relative to buprenorphine (Steagall et al. 2014). The over-dispersion of 426 
response times likely explains why buprenorphine did not achieve statistical 427 
significance overall and why the effects of morphine were unable to be statistically 428 
established through corrected post-hoc analysis. However, analysis of effect size did 429 
identify that the changes in response time seen for tramadol, morphine and 430 
buprenorphine were similar. This suggests that the lack of significance is likely 431 
caused by sample sizes being too small rather than providing evidence of a lack of 432 
effect. Smaller cohort studies of thermal nociceptive thresholds commonly use cross-433 
over studies which function to minimise the inter-individual variability. It may be 434 
judicious to use such a design with a thermal carbon dioxide laser. 435 
 436 
Medetomidine showed no significant effect on thermal thresholds, however the 437 
amount used in this study was well below that used in other studies (e.g. Ansah et al. 438 
2002). In part this was to avoid excessive levels of sedation which are known to 439 
impact upon animals’ ability to demonstrate nociceptive response (Hunt et al. 2013). 440 
Intramuscular administration of medetomidine at 50 µg/kg or over has been shown to 441 
result in peak sedation scores (Ansah et al. 1998) and it is often utilised as an 442 
adjunctive sedative during anaesthesia (Wiese & Muir 2007). In cats, analgesia is 443 
achieved at both 15 and 10 µg/kg (Ansah et al. 2002; Steagall et al. 2009b). 444 
Medetomidine was included at a substantially lower dosage here (2 µg/kg) in an 445 
attempt to assess the sensitivity of the CO2 laser protocol. This result suggests that 446 
either medetomidine had no analgesic or sedative effect at this dose or that this 447 
thermal technique is not able to elucidate small changes in nociception. 448 
Retrospectively a validated dose rate of 10 µg/kg (Cullen 1996) would have been 449 
appropriate.   450 
 451 
Although preliminary results appear promising, there are a number of areas which 452 
require further exploration and some findings indicate potential drawbacks. This 453 
technique lacks the direct contact of attached thermal devices which means that, 454 
whilst it does not disrupt normal behavioural patterns, it is difficult to take 455 
measurements at exact time points dependent upon the subject’s movement patterns. 456 
We were also unable to ascertain the effect of skin temperature variations on latency 457 
to respond to a remote thermal stimulus. This is of particular interest given that 458 
opioids such as morphine and buprenorphine cause significant increases in body 459 
temperature (Posner et al. 2010) and other drugs such as dexmedetomidine have been 460 
shown to impact upon thermoregulatory processes (Talke et al. 1997).  461 
 462 
This study used a similar number of subjects per treatment when compared to other 463 
thermal threshold studies. It may be judicious to increase sample size in future 464 
protocols, especially given the variability of response. This study appears adequately 465 
powered to establish differences between control treatments and analgesic treatments 466 
but may not be sufficiently powered to detect differences between opioids, or to 467 
account for a large degree of inter-individual variation. When multiple comparisons 468 
were made, significant effects were often lost when p-values were corrected. However 469 
comparisons between this and other studies make a strong case that a CO2 laser is a 470 
valid experimental tool for assessing pharmacological effect.  471 
 472 
It is important to note there was some evidence of blistering in cats exposed for the 473 
full 60 s, possibly as a result of reduced reactivity brought about by the analgesic 474 
and/or sedative effects of treatment. This effect was not previously observed in other 475 
similar experiments (Farnworth et al. 2013a) but suggests a need to establish at what 476 
time point damage occurs and to reduce the exposure time accordingly. However, the 477 
use of an earlier cut-off point will likely require the use of a statistical technique that 478 
can account for higher numbers of right censored data points (those reaching the cut-479 
off point) from cats provided with analgesics. Although attempts were made to 480 
minimise the likelihood that a single point of stimulation would be reused The 481 
inability to definitively ensure such may have resulted in some sensitisation to the 482 
thermal stimulus. Future exploration may include placing one ink mark on the 483 
subjects skin for each test to be undertaken. Targeting of the mark with the visible 484 
laser would preclude unintentional overlap of stimulation sites. 485 
 486 
The 15 min intervals used may have had some effect on the median response times, 487 
although all attempts were made to minimise this. Future studies using this technique 488 
should attempt to measure sedation and perhaps address a narrower array of 489 
analgesics using a broader set of dose rates. They may also wish to address how this 490 
technique applies to analgesia following surgical interventions and animals already 491 
experiencing pain. It would also be useful to develop this technique in conjunction 492 
with thermographic imaging to quantify any effects of changes in skin temperature 493 
resulting from external temperature fluctuations or physiological changes as a result 494 
of drug administration. It is reasonable to conclude that the research hypotheses were 495 
supported by our findings and that a carbon dioxide laser is able to determine changes 496 
in anti-nociceptive thresholds of cats tested following administration of opioids. The 497 
utility of this technique requires, and warrants, further exploration 498 
 499 
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 629 
  630 
Table 1. Median and range for behavioural latency of cats to respond to a carbon 631 
dioxide laser. Values are median (minimum to maximum) in seconds for cats across 632 
monitoring period that extended to a maximum of 135 min. 633 
 634 
Treatment Pre-Test 15-30 min 30-45 min 45-60 min 60-75 min 90-105 min 120-135 min 
sec sec sec sec sec sec sec 
Saline 11.8 (2.6-43) 8.5 (3.4-17.3) 6.1 (4.3-12.9) 8.3 (2.9-30.5) 6.2 (4.8-20.4) 14.2 (7.5-36.6) 12.0 (4.8->60) 
Morphine  10.2 (1.3-27.8) 22.6 (3.1->60) 15.4 (3.1->60) 17.7 (7.4->60) >60 (17.9->60) 34.0 (4.0->60) 58 (4.9->60) 
Buprenorphine  11.2 (2.4-34) 29.6 (2.3->60) >60 (3.0->60) >60 (3.1->60) 38.6 (4.8->60) >60 (7.1->60) 45.5 (10.3->60) 
Medetomidine  6.8 (2.2-27.7) 17.3 (4.6->60) 8.9 (5.1-37.3) 9.0 (2.3->60) 11 (4.9->60) 9.1 (4.5->60) 9.2 (3.7->60) 
Tramadol  11.0 (3.6-18.1) 9.9 (2.8->60) 17.1 (3.1->60) 14.1 (4.9->60) 21.9 (12.2->60) 43.6 (12 - >60) 29.7 (9.5->60) 
Ketoprofen  10.6 (2.1-23) 12.9 (2.6-21.8) 8.2 (3.43->60) 6.4 (3.2-30.7) 22.3 (3.8-51.7) 9.5 (3.1->60) 11.6 (2.3->60) 
 635 
  636 
Table 2: Number of tests (numerator) for a given time period where subjects (cats) 637 
reached the 60s cut-off time. Testing occurred after an intramuscular injection of one 638 
of six treatment compounds and was executed using a 500 mW thermal carbon 639 
dioxide laser. The denominator is the total number of tests obtained for that time 640 
period. 641 
 642 
 643 
 644 
Treatment 
Time Phase (min) 
Pre 15-30 30-45 45-60 60-75 90-105 120-135 
Saline (0.2ml/cat) 0/10 0/8 0/10 0/7 0/9 0/10 2/10 
Morphine (0.5mg/kg) 0/10 1/9 2/10 4/10 7/10 4/10 4/10 
Buprenorphine (20µg/kg) 0/10 4/9 6/10 5/10 4/10 5/9 3/10 
Tramadol (2mg/kg) 0/10 2/10 1/10 3/10 4/10 5/10 2/10 
Ketoprofen (2mg/kg) 0/10 0/9 0/9 0/9 0/10 1/10 1/9 
Medetomidine (2µg/kg) 0/10 1/9 0/10 1/9 1/10 1/10 2/10 
  645 
Table 3. Effect sizes for pair size comparisons presented in Table 3.  Figures for 646 
Bupremorphine are also included as normal hypotheses testing indicated significance 647 
remained below 0.1. Effects sizes = 0.2 are considered small, = 0.5 medium and = 0.8 648 
large. 649 
 650 
Treatment Pre-test vs 30-45 
min 
Pre-test vs 60-75 
min 
Pre-test vs 120-135 
min 
 Effect size r Effect size r Effect size r 
Morphine -0.148 -0.604 -0.572 
Tremadol -0.307 -0.627 -0.627 
Buprenorphine -0.399 -0.537 -0.604 
 651 
  652 
 653 
 654 
 655 
Figure 1: Quartiles (box) and Median latency (horizontal bar) of cats to respond to 656 
thermal stimulation using a carbon dioxide laser across six treatments. For both 657 
tramadol and morphine ** denotes a statistically significant effect across the entire 658 
test period on latency to respond (P < 0.05). For buprenorphine * denotes a statistical 659 
trend (P < 0.1). Within treatments the letter (a) denotes statistical significance 660 
(P<0.05) between the response at the relevant time period and the pre-treatment 661 
response. 662 
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 667 
 668 
